drugset / Trial / NCT02107378
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
Timeline
- Start
- 2014-01
- Primary completion
- 2016-08
- Completion
- 2016-08
Outcome
Outcome not reported
Stopped (Business): “sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STAPULDENCEL | Vaccine | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Topotecan | Small molecule | — | — |